Global Tumor Immunotherapy Market Growth (Status and Outlook) 2025-2031

September 2025 | 159 pages | ID: G867E7DC2092EN
LP Information

Abstracts

According to this study, the global Tumor Immunotherapy market size will reach US$ million by 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Tumor Immunotherapy Industry Forecast” looks at past sales and reviews total world Tumor Immunotherapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Tumor Immunotherapy sales for 2025 through 2031. With Tumor Immunotherapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Immunotherapy industry.

This Insight Report provides a comprehensive analysis of the global Tumor Immunotherapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Tumor Immunotherapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Immunotherapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Immunotherapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Immunotherapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Immunotherapy market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Tumor Infiltrating Lymphocyte (TIL) Treatment
• Engineered T Cell Receptor (TCR) Therapy
• Chimeric Antigen Receptor (CAR) T Cell Therapy
• Natural Killer (NK) Cell Therapy
• Other

Segmentation by Application:

• Biopharmaceutical Company
• Hospital
• Universities And Other Scientific Research Institutions
• Other

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Roche
• Merck
• Novartis
• Johnson & Johnson
• GlaxoSmithKline
• AbbVie
• ELI Lilly
• Amgen
• AstraZeneca
• Bristol-Mysers Squibb
• Kite Pharma
• Adaptimmune
• Altor Bioscience Corporation
• Cellectis
• Juno Therapeutics
• Takara Bio
• Unum Therapeutics
• Sunway
• Junshi Bio
• Cinda Bio
• BeiGene

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Tumor Immunotherapy Market Size (2020-2031)
  2.1.2 Tumor Immunotherapy Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Tumor Immunotherapy by Country/Region (2020, 2024 & 2031)
2.2 Tumor Immunotherapy Segment by Type
  2.2.1 Tumor Infiltrating Lymphocyte (TIL) Treatment
  2.2.2 Engineered T Cell Receptor (TCR) Therapy
  2.2.3 Chimeric Antigen Receptor (CAR) T Cell Therapy
  2.2.4 Natural Killer (NK) Cell Therapy
  2.2.5 Other
2.3 Tumor Immunotherapy Market Size by Type
  2.3.1 Tumor Immunotherapy Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Tumor Immunotherapy Market Size Market Share by Type (2020-2025)
2.4 Tumor Immunotherapy Segment by Application
  2.4.1 Biopharmaceutical Company
  2.4.2 Hospital
  2.4.3 Universities And Other Scientific Research Institutions
  2.4.4 Other
2.5 Tumor Immunotherapy Market Size by Application
  2.5.1 Tumor Immunotherapy Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Tumor Immunotherapy Market Size Market Share by Application (2020-2025)

3 TUMOR IMMUNOTHERAPY MARKET SIZE BY PLAYER

3.1 Tumor Immunotherapy Market Size Market Share by Player
  3.1.1 Global Tumor Immunotherapy Revenue by Player (2020-2025)
  3.1.2 Global Tumor Immunotherapy Revenue Market Share by Player (2020-2025)
3.2 Global Tumor Immunotherapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 TUMOR IMMUNOTHERAPY BY REGION

4.1 Tumor Immunotherapy Market Size by Region (2020-2025)
4.2 Global Tumor Immunotherapy Annual Revenue by Country/Region (2020-2025)
4.3 Americas Tumor Immunotherapy Market Size Growth (2020-2025)
4.4 APAC Tumor Immunotherapy Market Size Growth (2020-2025)
4.5 Europe Tumor Immunotherapy Market Size Growth (2020-2025)
4.6 Middle East & Africa Tumor Immunotherapy Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Tumor Immunotherapy Market Size by Country (2020-2025)
5.2 Americas Tumor Immunotherapy Market Size by Type (2020-2025)
5.3 Americas Tumor Immunotherapy Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Tumor Immunotherapy Market Size by Region (2020-2025)
6.2 APAC Tumor Immunotherapy Market Size by Type (2020-2025)
6.3 APAC Tumor Immunotherapy Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Tumor Immunotherapy Market Size by Country (2020-2025)
7.2 Europe Tumor Immunotherapy Market Size by Type (2020-2025)
7.3 Europe Tumor Immunotherapy Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Tumor Immunotherapy by Region (2020-2025)
8.2 Middle East & Africa Tumor Immunotherapy Market Size by Type (2020-2025)
8.3 Middle East & Africa Tumor Immunotherapy Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL TUMOR IMMUNOTHERAPY MARKET FORECAST

10.1 Global Tumor Immunotherapy Forecast by Region (2026-2031)
  10.1.1 Global Tumor Immunotherapy Forecast by Region (2026-2031)
  10.1.2 Americas Tumor Immunotherapy Forecast
  10.1.3 APAC Tumor Immunotherapy Forecast
  10.1.4 Europe Tumor Immunotherapy Forecast
  10.1.5 Middle East & Africa Tumor Immunotherapy Forecast
10.2 Americas Tumor Immunotherapy Forecast by Country (2026-2031)
  10.2.1 United States Market Tumor Immunotherapy Forecast
  10.2.2 Canada Market Tumor Immunotherapy Forecast
  10.2.3 Mexico Market Tumor Immunotherapy Forecast
  10.2.4 Brazil Market Tumor Immunotherapy Forecast
10.3 APAC Tumor Immunotherapy Forecast by Region (2026-2031)
  10.3.1 China Tumor Immunotherapy Market Forecast
  10.3.2 Japan Market Tumor Immunotherapy Forecast
  10.3.3 Korea Market Tumor Immunotherapy Forecast
  10.3.4 Southeast Asia Market Tumor Immunotherapy Forecast
  10.3.5 India Market Tumor Immunotherapy Forecast
  10.3.6 Australia Market Tumor Immunotherapy Forecast
10.4 Europe Tumor Immunotherapy Forecast by Country (2026-2031)
  10.4.1 Germany Market Tumor Immunotherapy Forecast
  10.4.2 France Market Tumor Immunotherapy Forecast
  10.4.3 UK Market Tumor Immunotherapy Forecast
  10.4.4 Italy Market Tumor Immunotherapy Forecast
  10.4.5 Russia Market Tumor Immunotherapy Forecast
10.5 Middle East & Africa Tumor Immunotherapy Forecast by Region (2026-2031)
  10.5.1 Egypt Market Tumor Immunotherapy Forecast
  10.5.2 South Africa Market Tumor Immunotherapy Forecast
  10.5.3 Israel Market Tumor Immunotherapy Forecast
  10.5.4 Turkey Market Tumor Immunotherapy Forecast
10.6 Global Tumor Immunotherapy Forecast by Type (2026-2031)
10.7 Global Tumor Immunotherapy Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Tumor Immunotherapy Forecast

11 KEY PLAYERS ANALYSIS

11.1 Roche
  11.1.1 Roche Company Information
  11.1.2 Roche Tumor Immunotherapy Product Offered
  11.1.3 Roche Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Roche Main Business Overview
  11.1.5 Roche Latest Developments
11.2 Merck
  11.2.1 Merck Company Information
  11.2.2 Merck Tumor Immunotherapy Product Offered
  11.2.3 Merck Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Merck Main Business Overview
  11.2.5 Merck Latest Developments
11.3 Novartis
  11.3.1 Novartis Company Information
  11.3.2 Novartis Tumor Immunotherapy Product Offered
  11.3.3 Novartis Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Novartis Main Business Overview
  11.3.5 Novartis Latest Developments
11.4 Johnson & Johnson
  11.4.1 Johnson & Johnson Company Information
  11.4.2 Johnson & Johnson Tumor Immunotherapy Product Offered
  11.4.3 Johnson & Johnson Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Johnson & Johnson Main Business Overview
  11.4.5 Johnson & Johnson Latest Developments
11.5 GlaxoSmithKline
  11.5.1 GlaxoSmithKline Company Information
  11.5.2 GlaxoSmithKline Tumor Immunotherapy Product Offered
  11.5.3 GlaxoSmithKline Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 GlaxoSmithKline Main Business Overview
  11.5.5 GlaxoSmithKline Latest Developments
11.6 AbbVie
  11.6.1 AbbVie Company Information
  11.6.2 AbbVie Tumor Immunotherapy Product Offered
  11.6.3 AbbVie Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 AbbVie Main Business Overview
  11.6.5 AbbVie Latest Developments
11.7 ELI Lilly
  11.7.1 ELI Lilly Company Information
  11.7.2 ELI Lilly Tumor Immunotherapy Product Offered
  11.7.3 ELI Lilly Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 ELI Lilly Main Business Overview
  11.7.5 ELI Lilly Latest Developments
11.8 Amgen
  11.8.1 Amgen Company Information
  11.8.2 Amgen Tumor Immunotherapy Product Offered
  11.8.3 Amgen Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.8.4 Amgen Main Business Overview
  11.8.5 Amgen Latest Developments
11.9 AstraZeneca
  11.9.1 AstraZeneca Company Information
  11.9.2 AstraZeneca Tumor Immunotherapy Product Offered
  11.9.3 AstraZeneca Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.9.4 AstraZeneca Main Business Overview
  11.9.5 AstraZeneca Latest Developments
11.10 Bristol-Mysers Squibb
  11.10.1 Bristol-Mysers Squibb Company Information
  11.10.2 Bristol-Mysers Squibb Tumor Immunotherapy Product Offered
  11.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.10.4 Bristol-Mysers Squibb Main Business Overview
  11.10.5 Bristol-Mysers Squibb Latest Developments
11.11 Kite Pharma
  11.11.1 Kite Pharma Company Information
  11.11.2 Kite Pharma Tumor Immunotherapy Product Offered
  11.11.3 Kite Pharma Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.11.4 Kite Pharma Main Business Overview
  11.11.5 Kite Pharma Latest Developments
11.12 Adaptimmune
  11.12.1 Adaptimmune Company Information
  11.12.2 Adaptimmune Tumor Immunotherapy Product Offered
  11.12.3 Adaptimmune Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.12.4 Adaptimmune Main Business Overview
  11.12.5 Adaptimmune Latest Developments
11.13 Altor Bioscience Corporation
  11.13.1 Altor Bioscience Corporation Company Information
  11.13.2 Altor Bioscience Corporation Tumor Immunotherapy Product Offered
  11.13.3 Altor Bioscience Corporation Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.13.4 Altor Bioscience Corporation Main Business Overview
  11.13.5 Altor Bioscience Corporation Latest Developments
11.14 Cellectis
  11.14.1 Cellectis Company Information
  11.14.2 Cellectis Tumor Immunotherapy Product Offered
  11.14.3 Cellectis Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.14.4 Cellectis Main Business Overview
  11.14.5 Cellectis Latest Developments
11.15 Juno Therapeutics
  11.15.1 Juno Therapeutics Company Information
  11.15.2 Juno Therapeutics Tumor Immunotherapy Product Offered
  11.15.3 Juno Therapeutics Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.15.4 Juno Therapeutics Main Business Overview
  11.15.5 Juno Therapeutics Latest Developments
11.16 Takara Bio
  11.16.1 Takara Bio Company Information
  11.16.2 Takara Bio Tumor Immunotherapy Product Offered
  11.16.3 Takara Bio Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.16.4 Takara Bio Main Business Overview
  11.16.5 Takara Bio Latest Developments
11.17 Unum Therapeutics
  11.17.1 Unum Therapeutics Company Information
  11.17.2 Unum Therapeutics Tumor Immunotherapy Product Offered
  11.17.3 Unum Therapeutics Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.17.4 Unum Therapeutics Main Business Overview
  11.17.5 Unum Therapeutics Latest Developments
11.18 Sunway
  11.18.1 Sunway Company Information
  11.18.2 Sunway Tumor Immunotherapy Product Offered
  11.18.3 Sunway Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.18.4 Sunway Main Business Overview
  11.18.5 Sunway Latest Developments
11.19 Junshi Bio
  11.19.1 Junshi Bio Company Information
  11.19.2 Junshi Bio Tumor Immunotherapy Product Offered
  11.19.3 Junshi Bio Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.19.4 Junshi Bio Main Business Overview
  11.19.5 Junshi Bio Latest Developments
11.20 Cinda Bio
  11.20.1 Cinda Bio Company Information
  11.20.2 Cinda Bio Tumor Immunotherapy Product Offered
  11.20.3 Cinda Bio Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.20.4 Cinda Bio Main Business Overview
  11.20.5 Cinda Bio Latest Developments
11.21 BeiGene
  11.21.1 BeiGene Company Information
  11.21.2 BeiGene Tumor Immunotherapy Product Offered
  11.21.3 BeiGene Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
  11.21.4 BeiGene Main Business Overview
  11.21.5 BeiGene Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Tumor Immunotherapy Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Tumor Immunotherapy Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Tumor Infiltrating Lymphocyte (TIL) Treatment
Table 4. Major Players of Engineered T Cell Receptor (TCR) Therapy
Table 5. Major Players of Chimeric Antigen Receptor (CAR) T Cell Therapy
Table 6. Major Players of Natural Killer (NK) Cell Therapy
Table 7. Major Players of Other
Table 8. Tumor Immunotherapy Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Tumor Immunotherapy Market Size by Type (2020-2025) & ($ millions)
Table 10. Global Tumor Immunotherapy Market Size Market Share by Type (2020-2025)
Table 11. Tumor Immunotherapy Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 12. Global Tumor Immunotherapy Market Size by Application (2020-2025) & ($ millions)
Table 13. Global Tumor Immunotherapy Market Size Market Share by Application (2020-2025)
Table 14. Global Tumor Immunotherapy Revenue by Player (2020-2025) & ($ millions)
Table 15. Global Tumor Immunotherapy Revenue Market Share by Player (2020-2025)
Table 16. Tumor Immunotherapy Key Players Head office and Products Offered
Table 17. Tumor Immunotherapy Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Tumor Immunotherapy Market Size by Region (2020-2025) & ($ millions)
Table 21. Global Tumor Immunotherapy Market Size Market Share by Region (2020-2025)
Table 22. Global Tumor Immunotherapy Revenue by Country/Region (2020-2025) & ($ millions)
Table 23. Global Tumor Immunotherapy Revenue Market Share by Country/Region (2020-2025)
Table 24. Americas Tumor Immunotherapy Market Size by Country (2020-2025) & ($ millions)
Table 25. Americas Tumor Immunotherapy Market Size Market Share by Country (2020-2025)
Table 26. Americas Tumor Immunotherapy Market Size by Type (2020-2025) & ($ millions)
Table 27. Americas Tumor Immunotherapy Market Size Market Share by Type (2020-2025)
Table 28. Americas Tumor Immunotherapy Market Size by Application (2020-2025) & ($ millions)
Table 29. Americas Tumor Immunotherapy Market Size Market Share by Application (2020-2025)
Table 30. APAC Tumor Immunotherapy Market Size by Region (2020-2025) & ($ millions)
Table 31. APAC Tumor Immunotherapy Market Size Market Share by Region (2020-2025)
Table 32. APAC Tumor Immunotherapy Market Size by Type (2020-2025) & ($ millions)
Table 33. APAC Tumor Immunotherapy Market Size by Application (2020-2025) & ($ millions)
Table 34. Europe Tumor Immunotherapy Market Size by Country (2020-2025) & ($ millions)
Table 35. Europe Tumor Immunotherapy Market Size Market Share by Country (2020-2025)
Table 36. Europe Tumor Immunotherapy Market Size by Type (2020-2025) & ($ millions)
Table 37. Europe Tumor Immunotherapy Market Size by Application (2020-2025) & ($ millions)
Table 38. Middle East & Africa Tumor Immunotherapy Market Size by Region (2020-2025) & ($ millions)
Table 39. Middle East & Africa Tumor Immunotherapy Market Size by Type (2020-2025) & ($ millions)
Table 40. Middle East & Africa Tumor Immunotherapy Market Size by Application (2020-2025) & ($ millions)
Table 41. Key Market Drivers & Growth Opportunities of Tumor Immunotherapy
Table 42. Key Market Challenges & Risks of Tumor Immunotherapy
Table 43. Key Industry Trends of Tumor Immunotherapy
Table 44. Global Tumor Immunotherapy Market Size Forecast by Region (2026-2031) & ($ millions)
Table 45. Global Tumor Immunotherapy Market Size Market Share Forecast by Region (2026-2031)
Table 46. Global Tumor Immunotherapy Market Size Forecast by Type (2026-2031) & ($ millions)
Table 47. Global Tumor Immunotherapy Market Size Forecast by Application (2026-2031) & ($ millions)
Table 48. Roche Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 49. Roche Tumor Immunotherapy Product Offered
Table 50. Roche Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 51. Roche Main Business
Table 52. Roche Latest Developments
Table 53. Merck Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 54. Merck Tumor Immunotherapy Product Offered
Table 55. Merck Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 56. Merck Main Business
Table 57. Merck Latest Developments
Table 58. Novartis Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 59. Novartis Tumor Immunotherapy Product Offered
Table 60. Novartis Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 61. Novartis Main Business
Table 62. Novartis Latest Developments
Table 63. Johnson & Johnson Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 64. Johnson & Johnson Tumor Immunotherapy Product Offered
Table 65. Johnson & Johnson Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 66. Johnson & Johnson Main Business
Table 67. Johnson & Johnson Latest Developments
Table 68. GlaxoSmithKline Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 69. GlaxoSmithKline Tumor Immunotherapy Product Offered
Table 70. GlaxoSmithKline Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 71. GlaxoSmithKline Main Business
Table 72. GlaxoSmithKline Latest Developments
Table 73. AbbVie Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 74. AbbVie Tumor Immunotherapy Product Offered
Table 75. AbbVie Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 76. AbbVie Main Business
Table 77. AbbVie Latest Developments
Table 78. ELI Lilly Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 79. ELI Lilly Tumor Immunotherapy Product Offered
Table 80. ELI Lilly Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 81. ELI Lilly Main Business
Table 82. ELI Lilly Latest Developments
Table 83. Amgen Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 84. Amgen Tumor Immunotherapy Product Offered
Table 85. Amgen Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 86. Amgen Main Business
Table 87. Amgen Latest Developments
Table 88. AstraZeneca Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 89. AstraZeneca Tumor Immunotherapy Product Offered
Table 90. AstraZeneca Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 91. AstraZeneca Main Business
Table 92. AstraZeneca Latest Developments
Table 93. Bristol-Mysers Squibb Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 94. Bristol-Mysers Squibb Tumor Immunotherapy Product Offered
Table 95. Bristol-Mysers Squibb Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 96. Bristol-Mysers Squibb Main Business
Table 97. Bristol-Mysers Squibb Latest Developments
Table 98. Kite Pharma Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 99. Kite Pharma Tumor Immunotherapy Product Offered
Table 100. Kite Pharma Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 101. Kite Pharma Main Business
Table 102. Kite Pharma Latest Developments
Table 103. Adaptimmune Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 104. Adaptimmune Tumor Immunotherapy Product Offered
Table 105. Adaptimmune Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 106. Adaptimmune Main Business
Table 107. Adaptimmune Latest Developments
Table 108. Altor Bioscience Corporation Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 109. Altor Bioscience Corporation Tumor Immunotherapy Product Offered
Table 110. Altor Bioscience Corporation Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 111. Altor Bioscience Corporation Main Business
Table 112. Altor Bioscience Corporation Latest Developments
Table 113. Cellectis Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 114. Cellectis Tumor Immunotherapy Product Offered
Table 115. Cellectis Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 116. Cellectis Main Business
Table 117. Cellectis Latest Developments
Table 118. Juno Therapeutics Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 119. Juno Therapeutics Tumor Immunotherapy Product Offered
Table 120. Juno Therapeutics Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 121. Juno Therapeutics Main Business
Table 122. Juno Therapeutics Latest Developments
Table 123. Takara Bio Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 124. Takara Bio Tumor Immunotherapy Product Offered
Table 125. Takara Bio Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 126. Takara Bio Main Business
Table 127. Takara Bio Latest Developments
Table 128. Unum Therapeutics Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 129. Unum Therapeutics Tumor Immunotherapy Product Offered
Table 130. Unum Therapeutics Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 131. Unum Therapeutics Main Business
Table 132. Unum Therapeutics Latest Developments
Table 133. Sunway Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 134. Sunway Tumor Immunotherapy Product Offered
Table 135. Sunway Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 136. Sunway Main Business
Table 137. Sunway Latest Developments
Table 138. Junshi Bio Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 139. Junshi Bio Tumor Immunotherapy Product Offered
Table 140. Junshi Bio Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 141. Junshi Bio Main Business
Table 142. Junshi Bio Latest Developments
Table 143. Cinda Bio Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 144. Cinda Bio Tumor Immunotherapy Product Offered
Table 145. Cinda Bio Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 146. Cinda Bio Main Business
Table 147. Cinda Bio Latest Developments
Table 148. BeiGene Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 149. BeiGene Tumor Immunotherapy Product Offered
Table 150. BeiGene Tumor Immunotherapy Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 151. BeiGene Main Business
Table 152. BeiGene Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Tumor Immunotherapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Tumor Immunotherapy Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Tumor Immunotherapy Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Tumor Immunotherapy Sales Market Share by Country/Region (2024)
Figure 8. Tumor Immunotherapy Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Tumor Immunotherapy Market Size Market Share by Type in 2024
Figure 10. Tumor Immunotherapy in Biopharmaceutical Company
Figure 11. Global Tumor Immunotherapy Market: Biopharmaceutical Company (2020-2025) & ($ millions)
Figure 12. Tumor Immunotherapy in Hospital
Figure 13. Global Tumor Immunotherapy Market: Hospital (2020-2025) & ($ millions)
Figure 14. Tumor Immunotherapy in Universities And Other Scientific Research Institutions
Figure 15. Global Tumor Immunotherapy Market: Universities And Other Scientific Research Institutions (2020-2025) & ($ millions)
Figure 16. Tumor Immunotherapy in Other
Figure 17. Global Tumor Immunotherapy Market: Other (2020-2025) & ($ millions)
Figure 18. Global Tumor Immunotherapy Market Size Market Share by Application in 2024
Figure 19. Global Tumor Immunotherapy Revenue Market Share by Player in 2024
Figure 20. Global Tumor Immunotherapy Market Size Market Share by Region (2020-2025)
Figure 21. Americas Tumor Immunotherapy Market Size 2020-2025 ($ millions)
Figure 22. APAC Tumor Immunotherapy Market Size 2020-2025 ($ millions)
Figure 23. Europe Tumor Immunotherapy Market Size 2020-2025 ($ millions)
Figure 24. Middle East & Africa Tumor Immunotherapy Market Size 2020-2025 ($ millions)
Figure 25. Americas Tumor Immunotherapy Value Market Share by Country in 2024
Figure 26. United States Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 27. Canada Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 28. Mexico Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 29. Brazil Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 30. APAC Tumor Immunotherapy Market Size Market Share by Region in 2024
Figure 31. APAC Tumor Immunotherapy Market Size Market Share by Type (2020-2025)
Figure 32. APAC Tumor Immunotherapy Market Size Market Share by Application (2020-2025)
Figure 33. China Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 34. Japan Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 35. South Korea Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 36. Southeast Asia Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 37. India Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 38. Australia Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 39. Europe Tumor Immunotherapy Market Size Market Share by Country in 2024
Figure 40. Europe Tumor Immunotherapy Market Size Market Share by Type (2020-2025)
Figure 41. Europe Tumor Immunotherapy Market Size Market Share by Application (2020-2025)
Figure 42. Germany Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 43. France Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 44. UK Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 45. Italy Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 46. Russia Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 47. Middle East & Africa Tumor Immunotherapy Market Size Market Share by Region (2020-2025)
Figure 48. Middle East & Africa Tumor Immunotherapy Market Size Market Share by Type (2020-2025)
Figure 49. Middle East & Africa Tumor Immunotherapy Market Size Market Share by Application (2020-2025)
Figure 50. Egypt Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 51. South Africa Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 52. Israel Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 53. Turkey Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 54. GCC Countries Tumor Immunotherapy Market Size Growth 2020-2025 ($ millions)
Figure 55. Americas Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 56. APAC Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 57. Europe Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 58. Middle East & Africa Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 59. United States Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 60. Canada Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 61. Mexico Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 62. Brazil Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 63. China Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 64. Japan Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 65. Korea Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 66. Southeast Asia Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 67. India Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 68. Australia Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 69. Germany Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 70. France Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 71. UK Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 72. Italy Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 73. Russia Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 74. Egypt Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 75. South Africa Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 76. Israel Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 77. Turkey Tumor Immunotherapy Market Size 2026-2031 ($ millions)
Figure 78. Global Tumor Immunotherapy Market Size Market Share Forecast by Type (2026-2031)
Figure 79. Global Tumor Immunotherapy Market Size Market Share Forecast by Application (2026-2031)
Figure 80. GCC Countries Tumor Immunotherapy Market Size 2026-2031 ($ millions)